TOMTEC-ARENA vs ElucidVivo A.3
AI Verdict
Choose TOMTEC-ARENA if…
Choose TOMTEC-ARENA if your institution requires a comprehensive, vendor-neutral platform for advanced medical image analysis across multiple modalities and specialties, including cardiology and radiology. This tool is ideal for organizations seeking AI-powered quantification, structured reporting, and web-based workflows to enhance diagnostic efficiency and data management for 2D, 3D, and 4D imaging data.
View TOMTEC-ARENA →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if your primary focus is on precise, AI-powered quantitative analysis of arterial plaque composition and stability from CT angiography to improve atherosclerosis patient stratification. This tool is specifically designed for clinicians needing detailed visualization of plaque characteristics, including Lipid-Rich Necrotic Core (LRNC) and calcifications, and FFRct derivation to optimize cardiovascular treatment decisions.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | TOMTEC-ARENA | ElucidVivo A.3 |
|---|---|---|
| Deployment | On-premise | Cloud and on-premise secure deployment. |
| FDA Status | Unknown | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
TOMTEC-ARENATOMTEC-ARENA explicitly highlights 'web-based diagnostic workflows (TOMTEC ZERO)' and 'multimodality and vendor-neutral imaging and analysis', which generally contribute to greater accessibility and ease of integration into existing clinical environments. ElucidVivo A.3 focuses on specific, advanced visualization features but does not detail overall workflow usability as comprehensively.
Clinical Value
ElucidVivo A.3ElucidVivo A.3 offers highly specific and validated quantitative analysis of arterial plaque composition and stability, including quantification of Lipid-Rich Necrotic Core (LRNC) and derivation of fractional flow reserve (FFRct), explicitly stating 'validated on ground-truth histology'. This provides a strong, evidence-based clinical impact for atherosclerosis patient stratification. TOMTEC-ARENA offers broad AI-based quantification but lacks this level of specific clinical validation detail.
Pricing & Value
TOMTEC-ARENATOMTEC-ARENA provides more transparency regarding its pricing approach, mentioning 'concurrent user licenses', 'automated archiving', 'measurement mapping services', and 'flexible, scalable, and tailored licensing options', including 'small business' models. ElucidVivo A.3 only states 'contact for pricing' without further details, making it difficult to assess its value proposition.
Enterprise Readiness
TOMTEC-ARENATOMTEC-ARENA explicitly lists diverse deployment options including 'On-premise (workstation), Cloud-hybrid (web-based access via TOMTEC ZERO), Client-server network', alongside 'automated archiving and data management' and 'DICOM connectivity and PACS/EMR integration'. These features indicate a robust and adaptable solution for various enterprise IT infrastructures. While ElucidVivo A.3 integrates with PACS/EMR, its deployment details are less comprehensive.
Innovation
ElucidVivo A.3ElucidVivo A.3 demonstrates higher innovation through its specialized AI-powered quantitative analysis of arterial plaque composition, including the ability to objectively quantify specific plaque components like LRNC and derive FFRct, validated against histology. This offers novel and advanced insights for cardiovascular risk assessment. TOMTEC-ARENA focuses on broader AI automation and workflow enhancements, which are valuable but less groundbreaking in terms of specific clinical insight.
Support & Docs
TOMTEC-ARENATOMTEC-ARENA explicitly mentions a 'premium TOMTEC service with an Up-to-Date maintenance contract', indicating a structured and ongoing support offering. ElucidVivo A.3 provides no information regarding its support services or documentation in the provided facts, making it impossible to evaluate this dimension for Tool B.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | TOMTEC-ARENA | ElucidVivo A.3 |
|---|---|---|
| Name | TOMTEC-ARENA | ElucidVivo A.3 |
| Company | TOMTEC Imaging Systems GmbH | Elucid Bioimaging |
| Description | AI-powered, multimodality, vendor-neutral software for advanced medical image analysis, quantification, and reporting, primarily for cardiology and radiology, with web-based workflows. | FDA-cleared AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography. It assists physicians in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics validated against histology. |
| Primary Specialties | Cardiology, Radiology | Cardiology, Radiology, Vascular Surgery |
| Key Features (Specific) | AI-based measurement automation and data analytics, Multimodality and vendor-neutral imaging and analysis, Web-based diagnostic workflows (TOMTEC ZERO), Advanced quantification for various medical specialties, Structured reporting capabilities, DICOM connectivity and PACS/EMR integration, Automated archiving and data management, Support for 2D, 3D, and 4D image data | AI-powered quantitative analysis of arterial plaque, Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, Visualizes lesion-level plaque composition, Provides 3D visualization of highlighted vessels, Offers rotatable curved MPR vessel views and cross-sections, Aids in stratifying patients with atherosclerosis, Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity, Validated on ground-truth histology |
Videos
Demos, reviews, and walkthroughs featuring TOMTEC-ARENA and ElucidVivo A.3.